Dr. Oberstein on Remaining Challenges in Metastatic CRC

In Partnership With:

Partner | Cancer Centers | <b>NYU Langone's Perlmutter Cancer Center</b>

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

Paul E. Oberstein, MD, associate professor, Department of Medicine, director, Gastrointestinal Medical Oncology Program, assistant director, Pancreatic Cancer Center, NYU Grossman School of Medicine, NYU Langone Health’s Perlmutter Cancer Center, discusses remaining challenges in metastatic colorectal cancer (CRC).

Although targeted therapies and immunotherapy have shown favorable results, they have only been beneficial for a minority of patients, Oberstein says. Therefore, it is important to find more treatment approaches that are effective for a wider subset of patients, Oberstein explains.

Moreover, although the incidence of CRC has gone down among the overall population, the incidence of CRC is rising among adults under the age of 50 years in the United States, Oberstein continues. It is important to understand more about why this has happened, as well as how to target those patients, Oberstein says.